IN2013MN00782A - - Google Patents

Download PDF

Info

Publication number
IN2013MN00782A
IN2013MN00782A IN782MUN2013A IN2013MN00782A IN 2013MN00782 A IN2013MN00782 A IN 2013MN00782A IN 782MUN2013 A IN782MUN2013 A IN 782MUN2013A IN 2013MN00782 A IN2013MN00782 A IN 2013MN00782A
Authority
IN
India
Prior art keywords
dementia
beta
compounds
compositions
disease
Prior art date
Application number
Other languages
English (en)
Inventor
SUÁREZ Andrés Avelino TRABANCO
Gary John Tresadern
JIMÉNEZ Francisca DELGADO
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IN2013MN00782A publication Critical patent/IN2013MN00782A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN782MUN2013 2010-09-22 2011-09-20 IN2013MN00782A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10178315 2010-09-22
EP11157858 2011-03-11
PCT/EP2011/066343 WO2012038438A1 (fr) 2010-09-22 2011-09-20 Dérivés de la 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-yl-amine utilisables en tant qu'inhibiteurs de la bêta-sécrétase (bace)

Publications (1)

Publication Number Publication Date
IN2013MN00782A true IN2013MN00782A (fr) 2015-06-12

Family

ID=45873470

Family Applications (1)

Application Number Title Priority Date Filing Date
IN782MUN2013 IN2013MN00782A (fr) 2010-09-22 2011-09-20

Country Status (21)

Country Link
US (1) US8609660B2 (fr)
EP (1) EP2619207B1 (fr)
JP (1) JP5797756B2 (fr)
KR (1) KR101962216B1 (fr)
CN (1) CN103097389B (fr)
AU (1) AU2011306941B2 (fr)
BR (1) BR112013006353A2 (fr)
CA (1) CA2807904C (fr)
CL (1) CL2013000782A1 (fr)
CO (1) CO6660450A2 (fr)
EA (1) EA021723B1 (fr)
ES (1) ES2529641T3 (fr)
IL (1) IL225349A (fr)
IN (1) IN2013MN00782A (fr)
MX (1) MX2013003246A (fr)
MY (1) MY160138A (fr)
NZ (1) NZ606848A (fr)
PH (1) PH12013500345A1 (fr)
SG (1) SG188338A1 (fr)
WO (1) WO2012038438A1 (fr)
ZA (1) ZA201302128B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2628074C (fr) 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Derive aminodihydrothiazine
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
JP5383484B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 環式基で置換されたアミノジヒドロチアジン誘導体
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
MX339640B (es) 2010-06-09 2016-06-01 Janssen Pharmaceutica Nv * Derivados de 5, 6-dihidro-2h-[1, 4] oxazin-3-il-amina utiles como inhibidores de la beta-secretasa (bace).
EP2634188A4 (fr) 2010-10-29 2014-05-07 Shionogi & Co Dérivé d'aminodihydropyrimidine fusionnée
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
EP2655376B1 (fr) 2010-12-22 2017-08-23 Janssen Pharmaceutica NV Dérivés de 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine comme inhibiteurs de la bêta-secrétase (bace)
AU2012224632B2 (en) 2011-03-09 2016-06-16 Janssen Pharmaceutica Nv 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
RU2639509C2 (ru) 2011-06-27 2017-12-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. МикроРНК - БИОМАРКЕРЫ, УКАЗЫВАЮЩИЕ НА БОЛЕЗНЬ АЛЬЦГЕЙМЕРА
EP2912035A4 (fr) 2012-10-24 2016-06-15 Shionogi & Co Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1
BR112015030597A2 (pt) 2013-06-12 2017-07-25 Janssen Pharmaceutica Nv derivados 4-amino-6-fenil-6,7-di-hidro[1,2,3]triazolo[1,5-a]pirazina como inibidores de beta-secretase (bace)
KR102243134B1 (ko) 2013-06-12 2021-04-22 얀센 파마슈티카 엔.브이. 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진 유도체
MX368326B (es) 2013-06-12 2019-09-27 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5-a]pirazin-3(2h )-ona como inhibidores de beta-secretasa (bace).
ES2768823T3 (es) 2014-12-18 2020-06-23 Janssen Pharmaceutica Nv Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa
WO2018165520A1 (fr) 2017-03-10 2018-09-13 Vps-3, Inc. Composés inhibiteurs de métalloenzymes
WO2019025250A1 (fr) 2017-08-04 2019-02-07 Basf Se Trifluorométhyloxadiazoles substitués permettant de lutter contre des champignons phytopathogènes
CN108440320A (zh) * 2018-05-09 2018-08-24 上海凌凯医药科技有限公司 一种高手性选择性合成α-双取代α-氨基酸的方法
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑hdac6抑制劑及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
WO2006138265A2 (fr) * 2005-06-14 2006-12-28 Schering Corporation Preparation et utilisation de composes en tant qu'inhibiteurs de proteases
TW200804290A (en) * 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
WO2011002409A1 (fr) * 2009-07-02 2011-01-06 Astrazeneca Ab Inhibiteurs de bêta-secrétase dérivés de 5h-pyrrolo[3,4-b>]pyrazine-7-amine

Also Published As

Publication number Publication date
MY160138A (en) 2017-02-28
IL225349A (en) 2016-07-31
KR20130110161A (ko) 2013-10-08
NZ606848A (en) 2015-01-30
ZA201302128B (en) 2014-08-27
EA201390419A1 (ru) 2013-07-30
CN103097389A (zh) 2013-05-08
AU2011306941B2 (en) 2014-06-12
CO6660450A2 (es) 2013-04-30
KR101962216B1 (ko) 2019-03-26
PH12013500345A1 (en) 2022-03-30
CL2013000782A1 (es) 2013-08-09
US8609660B2 (en) 2013-12-17
EA021723B1 (ru) 2015-08-31
MX2013003246A (es) 2013-05-22
BR112013006353A2 (pt) 2024-01-16
CN103097389B (zh) 2015-10-14
JP5797756B2 (ja) 2015-10-21
EP2619207A1 (fr) 2013-07-31
SG188338A1 (en) 2013-04-30
JP2013540740A (ja) 2013-11-07
IL225349A0 (en) 2013-06-27
ES2529641T3 (es) 2015-02-24
AU2011306941A1 (en) 2013-02-28
CA2807904C (fr) 2018-09-11
US20130190318A1 (en) 2013-07-25
WO2012038438A1 (fr) 2012-03-29
EP2619207B1 (fr) 2014-11-12
CA2807904A1 (fr) 2012-03-29
HK1182391A1 (zh) 2013-11-29

Similar Documents

Publication Publication Date Title
IN2013MN00782A (fr)
PH12012502377A1 (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
PH12013501805A1 (en) 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
MY161407A (en) 6,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
PH12012502379A1 (en) 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace)
MX2013007294A (es) Derivados de 5,6-dihidro-imidazo[1,2-a]pirazin-8ilaminautiles como inhibidores de beta-secretasa (bace).
MY165209A (en) 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
MX2014006752A (es) Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2h-[1,4]oxazin- 3-amina.
BR112012033291A2 (pt) derivados de 3-amino-5,6-di-hidro-1h-piranzin-2-ona úteis para o tratamento de doença de alzheimer e outras formas de demência
MX2015017151A (es) Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5 a]pirazin-3(2h)-ona como inhibidores de beta-secretasa (bace).
MX369629B (es) Derivados de 4-a mino-6-fenil-5,6-dihidroimidazo[1,5 a]pirazina como inhibidores de beta-secretasa (bace).
MX366063B (es) Derivados de 4-amino-6-fenil-6,7-dihidro[1,2,3]triazolo[1,5-a]pira zina como inhibidores de beta-secretasa (bace).
MX2019005247A (es) Compuestos 4,4a,5,7-tetrahidro-3h-furo[3,4-b]piridinilicos.